Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

Recruiting phase 2 trial (ReACT) of risk-adapted therapy in HPV-positive oropharyngeal cancer using a circulating tumor HPV DNA profile. No primary efficacy paper was identified.

Jonathan Schoenfeld, MD, MPH